World first for allogeneic iPSC-derived cell therapy: Cynata gains clinical trial approval from UK regulatory authority

Melbourne, Australia; 19 September 2016: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP) has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with its Phase 1 clinical trial of CYP-001 in patients with steroid-resistant graft-versus-host disease (GvHD). CYP-001 is Cynata’s lead CymerusTM mesenchymal stem cell (MSC) product.

Download Announcement